Pharmaceutical company Mallinckrodt has announced the creation of a €10 million state-of-the-art R&D facility at its recently opened offices in College Business and Technology Park in Blanchardstown, Dublin. The facility will house global device engineering for the company and bring 40 more new jobs to the site, taking the overall total of new positions there to 120 by 2017. This commitment brings Mallinckrodt’s total investment in the site to €85 million. The company has had a presence in Ireland for over 20 years and its new offices in Blanchardstown were officially opened this morning (September 19) by Social Protection Minister Leo Varadkar and Mallinckrodt president and chief executive officer, Mark Trudeau. “Today’s dedication and announcement reaffirms Ireland’s strategic importance to Mallinckrodt as we continue with our transition to become a high-growth, global specialty pharmaceutical business,” said Trudeau. “We are in the process of bringing global R&D activities for medical devices to this location and the team will focus on developing systems for delivery of certain specialty pharmaceutical therapies in our portfolio. Over more than two decades, our Irish colleagues have been a significant asset to our business. We are now entering a new and exciting era for Mallinckrodt in Ireland, which will continue to play an important role in the development of our global business,” he added. "This company is at the cutting edge of new and innovative treatments and the range of facilities being developed here is an exciting development,” said Minister Varadkar. “The Government has worked hard to create the right conditions for cutting edge pharma and biopharma companies to locate in Ireland. The provision of high quality jobs in this new R&D facility is very welcome. This investment means more jobs and more quality jobs in our community.”